Tetragastrin HCl | CAS#5609-49-4 | C-terminal tetrapeptide of gastrin

MedKoo Cat#: 597714 | Name: Tetragastrin HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tetragastrin HCl is the HCl salt of Tetragastrin, the C-terminal tetrapeptide of gastrin. It is the smallest peptide fragment of gastrin which has the same physiological and pharmacological activity as gastrin.

Chemical Structure

Tetragastrin HCl

CAS#5609-49-4

Theoretical Analysis

MedKoo Cat#: 597714

Name: Tetragastrin HCl

CAS#: 5609-49-4

Chemical Formula: C29H37ClN6O6S

Exact Mass: 632.2184

Molecular Weight: 633.16

Elemental Analysis: C, 55.01; H, 5.89; Cl, 5.60; N, 13.27; O, 15.16; S, 5.06

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1947-37-1 (free base)

Synonym

Tetragastrin hydrochloride; Tetragastrin HCl; Trp-Met-Asp-Phe hydrochloride;

IUPAC/Chemical Name

(S)-3-((S)-2-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-4-(methylthio)butanamido)-4-oxo-4-(((S)-1-oxo-1-(phenylamino)propan-2-yl)amino)butanoic acid hydrochloride

InChi Key

WHGNESKICGIAEC-WCFNAMMKSA-N

InChi Code

InChI=1S/C29H36N6O6S.ClH/c1-17(26(38)33-19-8-4-3-5-9-19)32-29(41)24(15-25(36)37)35-28(40)23(12-13-42-2)34-27(39)21(30)14-18-16-31-22-11-7-6-10-20(18)22;/h3-11,16-17,21,23-24,31H,12-15,30H2,1-2H3,(H,32,41)(H,33,38)(H,34,39)(H,35,40)(H,36,37);1H/t17-,21-,23-,24-;/m0./s1

SMILES Code

C[C@@H](C(NC1=CC=CC=C1)=O)NC([C@H](CC(O)=O)NC([C@H](CCSC)NC([C@H](CC2=CNC3=C2C=CC=C3)N)=O)=O)=O.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 633.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tenma T, Yodoya E, Tashima S, Fujita T, Murakami M, Yamamoto A, Muranishi S. Development of new lipophilic derivatives of tetragastrin: physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats. Pharm Res. 1993 Oct;10(10):1488-92. PubMed PMID: 8272412. 2: Komuro Y, Ishihara K, Ohara S, Saigenji K, Hotta K. Effects of tetragastrin on mucus glycoprotein in rat gastric mucosal protection. Gastroenterol Jpn. 1992 Oct;27(5):597-603. PubMed PMID: 1385248. 3: Tatsuta M, Iishi H, Yamamura H, Taniguchi H. Inhibition by tetragastrin of experimental carcinogenesis in rat colon: effect of wheat bran consumption. Int J Cancer. 1988 Feb 15;41(2):239-42. PubMed PMID: 2828245. 4: Tatsuta M, Iishi H, Baba M, Taniguchi H. Effect of 6-hydroxydopamine on gastric carcinogenesis and tetragastrin inhibition of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1989 Aug 1;49(15):4199-203. PubMed PMID: 2501024. 5: Tatsuta M, Iishi H, Yamamura H, Taniguchi H. Enhancement by propranolol of the inhibitory effect of tetragastrin on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1987 Jan 1;47(1):111-4. PubMed PMID: 3791197. 6: Setoh K, Murakami M, Araki N, Fujita T, Yamamoto A, Muranishi S. Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids. J Pharm Pharmacol. 1995 Oct;47(10):808-11. PubMed PMID: 8583347. 7: Komuro Y, Ishihara K, Kojima Y, Saigenji K, Hotta K. Distinct effects of tetragastrin in rat gastroduodenal mucosa on mucin content and mucosal protective action against histamine-induced injury. Dig Dis Sci. 1998 May;43(5):1050-6. PubMed PMID: 9590421. 8: Tatsuta M, Yamamura H, Baba M, Yamamoto R, Iishi H, Taniguchi H. Inhibitory effect of prolonged administration of tetragastrin on experimentally induced intestinal metaplasia in Wistar rats. Cancer. 1988 May 15;61(10):2051-6. PubMed PMID: 3359403. 9: Tatsuta M, Iishi H, Yamamura H, Yamamoto R, Taniguchi H. Enhancement by tetragastrin of experimental induction of gastric epithelium in the duodenum. Gut. 1989 Mar;30(3):311-5. PubMed PMID: 2707631; PubMed Central PMCID: PMC1378451. 10: Tatsuta M, Iishi H, Baba M, Taniguchi H. Effect of ornithine decarboxylase inhibitor on tetragastrin treatment of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1990 Feb 15;45(2):308-11. PubMed PMID: 2105911. 11: Agorastos A, Kellner M, Stiedl O, Muhtz C, Wiedemann K, Demiralay C. Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men. Int J Neuropsychopharmacol. 2014 Dec 11;18(5). pii: pyu053. doi: 10.1093/ijnp/pyu053. PubMed PMID: 25522396; PubMed Central PMCID: PMC4376541. 12: Desai SJ, Borkar CD, Nakhate KT, Subhedar NK, Kokare DM. Neuropeptide Y attenuates anxiety- and depression-like effects of cholecystokinin-4 in mice. Neuroscience. 2014 Sep 26;277:818-30. doi: 10.1016/j.neuroscience.2014.07.062. Epub 2014 Aug 7. PubMed PMID: 25106129. 13: Tatsuta M, Iishi H, Yamamura H, Baba M, Yamamoto R, Taniguchi H. Effect of cimetidine on inhibition by tetragastrin of carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Cancer Res. 1988 Mar 15;48(6):1591-5. PubMed PMID: 3345530. 14: Komuro Y, Ichikawa T, Ishihara K, Saigenji K, Hotta K. Influence of L-365,260, a CCK-B/gastrin receptor antagonist, on tetragastrin-stimulated mucin metabolism in rat gastric mucosa. Pharmacology. 1999 Jul;59(1):11-20. PubMed PMID: 10352422. 15: Karelin AA, Petukhova LM. [Tetragastrin activation of rat gastric mucosa adenyl cyclase in vitro]. Biull Eksp Biol Med. 1981 Apr;91(4):440-1. Russian. PubMed PMID: 7260361. 16: Tatsuta M, Iishi H, Ichii M, Noguchi S, Yamamura H, Taniguchi H. Effect of tetragastrin on the colonic mucosa of rats during intrarectal administration of N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res. 1986 Sep;46(9):4539-42. PubMed PMID: 3731107. 17: Bali JP, Mattras H, Previero A, Coletti-Previero MA. 'In vivo' amplification of biological activity of tetragastrin by amino acid hydroxamates. Biosci Rep. 1984 Dec;4(12):1009-15. PubMed PMID: 6529604. 18: Koizumi K, Okubo M, Inoue S, Masuda H. Trophic effect of tetragastrin on the stomach, duodenum and pancreas in rats. Tohoku J Exp Med. 1979 Sep;129(1):17-24. PubMed PMID: 494254. 19: Doyle JR, Harwood BN, Krishnaji ST, Krishnamurthy VM, Lin WE, Fortin JP, Kumar K, Kopin AS. A two-step strategy to enhance activity of low potency peptides. PLoS One. 2014 Nov 12;9(11):e110502. doi: 10.1371/journal.pone.0110502. eCollection 2014. PubMed PMID: 25391026; PubMed Central PMCID: PMC4229100. 20: Tatsuta M, Iishi H, Ichii M, Noguchi S, Yamamura H, Taniguchi H. Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methyl-N'-nitro-N-nitrosoguanidine. J Natl Cancer Inst. 1986 Feb;76(2):277-81. PubMed PMID: 3456065.